← Calendar
Readoutin 14d
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264
Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Non-Small Cell Lung Cancer
Source ↗Add to calendar
Date history
May 1, 2027 → Dec 1, 2026Nov 17, 2026
Dec 1, 2026 → May 1, 2027Nov 17, 2026
May 1, 2027 → Dec 1, 2026Nov 17, 2026
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
May2027
Readoutin 165d
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.